{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:31:30Z","timestamp":1786735890603,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Taiwan J Ophthalmol"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/tjo.tjo_69_18","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T07:43:20Z","timestamp":1543304600000},"page":"243","source":"Crossref","is-referenced-by-count":20,"title":["Bevacizumab or laser for aggressive posterior retinopathy of prematurity"],"prefix":"10.4103","volume":"8","author":[{"given":"Michael","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoseMaria Garcia","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney","family":"Schechet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Greenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SarahHilkert","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2211-5056.246301-1","first-page":"991","volume-title":"The international classification of retinopathy of prematurity revisited","author":"International","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"key-10.4103\/2211-5056.246301-2","doi-asserted-by":"crossref","unstructured":"Sanghi G, Dogra MR, Katoch D, Gupta A. Aggressive posterior retinopathy of prematurity: Risk factors for retinal detachment despite confluent laser photocoagulation. Am J Ophthalmol 2013;155:159-64.e2.","DOI":"10.1016\/j.ajo.2012.07.012"},{"key":"key-10.4103\/2211-5056.246301-3","first-page":"S37","volume-title":"Aggressive posterior retinopathy of prematurity","author":"Drenser","year":"2010","journal-title":"Retina"},{"key":"key-10.4103\/2211-5056.246301-4","first-page":"808639","volume-title":"Macular development in aggressive posterior retinopathy of prematurity","author":"Pandya","year":"2015","journal-title":"Biomed Res Int"},{"key":"key-10.4103\/2211-5056.246301-5","first-page":"603","volume-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2211-5056.246301-6","first-page":"1327","volume-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"key-10.4103\/2211-5056.246301-7","first-page":"1845","volume-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"key-10.4103\/2211-5056.246301-8","first-page":"280","volume-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"key-10.4103\/2211-5056.246301-9","first-page":"255","volume-title":"Reactivation of retinopathy of prematurity three years after treatment with bevacizumab","author":"Hajrasouliha","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"key-10.4103\/2211-5056.246301-10","first-page":"1000","volume-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"key-10.4103\/2211-5056.246301-11","first-page":"1080","volume-title":"Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment","author":"Hoang","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"key-10.4103\/2211-5056.246301-12","first-page":"323","volume-title":"Exudative retinopathy and detachment: A late reactivation of retinopathy of prematurity after intravitreal bevacizumab","author":"Ittiara","year":"2013","journal-title":"J AAPOS"},{"key":"key-10.4103\/2211-5056.246301-13","first-page":"801","volume-title":"Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity","author":"Patel","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"key-10.4103\/2211-5056.246301-14","first-page":"234","volume-title":"Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children","author":"Blair","year":"2012","journal-title":"J AAPOS"},{"key":"key-10.4103\/2211-5056.246301-15","first-page":"888","volume-title":"The former preterm infant and risk of post-operative apnoea: Recommendations for management","author":"Walther-Larsen","year":"2006","journal-title":"Acta Anaesthesiol Scand"},{"key":"key-10.4103\/2211-5056.246301-16","first-page":"809","volume-title":"Postoperative apnea in former preterm infants after inguinal herniorrhaphy.A combined analysis","author":"Cot\u00e9","year":"1995","journal-title":"Anesthesiology"},{"key":"key-10.4103\/2211-5056.246301-17","first-page":"459","volume-title":"Prevalence and outcomes of laser treatment of aggressive posterior retinopathy of prematurity","author":"Gunn","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"key":"key-10.4103\/2211-5056.246301-18","first-page":"300","volume-title":"Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity","author":"Gunay","year":"2015","journal-title":"Arq Bras Oftalmol"},{"key":"key-10.4103\/2211-5056.246301-19","first-page":"1192","volume-title":"Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8-year retrospective analysis","author":"Nicoar\u0103","year":"2016","journal-title":"Med Sci Monit"},{"key":"key-10.4103\/2211-5056.246301-20","first-page":"97","volume-title":"Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: A longitudinal fluorescein angiographic study","author":"Lorenz","year":"2017","journal-title":"Retina"},{"key":"key-10.4103\/2211-5056.246301-21","first-page":"764","volume-title":"Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity","author":"Garcia","year":"2018","journal-title":"Retina"},{"key":"key-10.4103\/2211-5056.246301-22","first-page":"2166","volume-title":"Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity","author":"Toy","year":"2016","journal-title":"Ophthalmology"},{"key":"key-10.4103\/2211-5056.246301-23","first-page":"1684","volume-title":"Revised indications for the treatment of retinopathy of prematurity: Results of the early treatment for retinopathy of prematurity randomized trial","author":"Early","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"key-10.4103\/2211-5056.246301-24","first-page":"1079","volume-title":"Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab","author":"Yonekawa","year":"2018","journal-title":"Retina"},{"key":"key-10.4103\/2211-5056.246301-25","doi-asserted-by":"crossref","unstructured":"Shapiro MJ, Blair MP, Gonzalez JM. Aggressive posterior retinopathy of prematurity (APROP). In retinopathy of prematurity (1st ed., pp. 49-70). Cham, Switzerland: Springer International Publishing 2017. doi:10.1007\/978-3-319-52190-9.","DOI":"10.1007\/978-3-319-52190-9"},{"key":"key-10.4103\/2211-5056.246301-26","first-page":"468","volume-title":"Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity","author":"Ells","year":"2017","journal-title":"Can J Ophthalmol"},{"key":"key-10.4103\/2211-5056.246301-27","first-page":"1741386","volume-title":"Asymmetric outcomes of type 1 retinopathy of prematurity after bilateral intravitreal ranibizumab treatment","author":"Huang","year":"2017","journal-title":"J Ophthalmol"},{"key":"key-10.4103\/2211-5056.246301-28","first-page":"5078565","volume-title":"Recurrence of retinopathy of prematurity in zone II stage 3+ after ranibizumab treatment: A retrospective study","author":"Hu","year":"2017","journal-title":"J Ophthalmol"},{"key":"key-10.4103\/2211-5056.246301-29","first-page":"1156","volume-title":"Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: Anatomic outcomes and influencing factors","author":"Huang","year":"2017","journal-title":"Ophthalmology"},{"key":"key-10.4103\/2211-5056.246301-30","first-page":"30","volume-title":"The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity","author":"Sukgen","year":"2017","journal-title":"Arq Bras Oftalmol"},{"key":"key-10.4103\/2211-5056.246301-31","first-page":"1719","volume-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: Timing and risk factors","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.4103\/2211-5056.246301-32","first-page":"1095","volume-title":"Nonresponse and recurrence of retinopathy of prematurity after intravitreal ranibizumab treatment","author":"Chuluunbat","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"key-10.4103\/2211-5056.246301-33","first-page":"710","volume-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity","author":"Zhang","year":"2017","journal-title":"Retina"},{"key":"key-10.4103\/2211-5056.246301-34","first-page":"694","volume-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"key-10.4103\/2211-5056.246301-35","first-page":"21","volume-title":"The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: A systematic review","author":"Kandasamy","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/2211-5056.246301-36","doi-asserted-by":"crossref","unstructured":"Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 2016;137. pii: e20153218.","DOI":"10.1542\/peds.2015-3218"},{"key":"key-10.4103\/2211-5056.246301-37","first-page":"e74","volume-title":"Re: Good: Bevacizumab for retinopathy of prematurity: Treatment when pathology is embedded in a normally developing vascular system (Ophthalmology 2016;123:1843-1844)","author":"Blair","year":"2017","journal-title":"Ophthalmology"},{"key":"key-10.4103\/2211-5056.246301-38","doi-asserted-by":"crossref","unstructured":"Msall ME, Phelps DL, DiGaudio KM, Dobson V, Tung B, McClead RE, et al. Severity of neonatal retinopathy of prematurity is predictive of neurodevelopmental functional outcome at age 5.5 years. Behalf of the Cryotherapy for Retinopathy of Prematurity Cooperative Group. Pediatrics 2000;106:998-1005.","DOI":"10.1542\/peds.106.5.998"},{"key":"key-10.4103\/2211-5056.246301-39","first-page":"276","volume-title":"The long-term outcome of extremely preterm (<28 weeks' gestational age) infants with and without severe retinopathy of prematurity","author":"Molloy","year":"2016","journal-title":"J Neuropsychol"},{"key":"key-10.4103\/2211-5056.246301-40","first-page":"F249","volume-title":"Ophthalmic impairment at 7 years of age in children born very preterm","author":"Cooke","year":"2004","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"key-10.4103\/2211-5056.246301-41","first-page":"346","volume-title":"Retinopathy of prematurity and neurodevelopmental disabilities in premature infants","author":"Beligere","year":"2015","journal-title":"Semin Fetal Neonatal Med"},{"key":"key-10.4103\/2211-5056.246301-42","first-page":"e0148019","volume-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","author":"Lien","year":"2016","journal-title":"PLoS One"},{"key":"key-10.4103\/2211-5056.246301-43","first-page":"61","volume-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","author":"Kennedy","year":"2018","journal-title":"J AAPOS"},{"key":"key-10.4103\/2211-5056.246301-44","first-page":"585","volume-title":"Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","author":"Araz-Ersan","year":"2015","journal-title":"Curr Eye Res"},{"key":"key-10.4103\/2211-5056.246301-45","first-page":"13","volume-title":"Comparison of ocular and developmental outcomes in laser-and bevacizumab-treated infants with retinopathy of prematurity","author":"Kong","year":"2015","journal-title":"Ophthalmol Res Int J"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:34:45Z","timestamp":1786732485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.tjo_69_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"alternative-id":["246301"],"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo_69_18","relation":{},"ISSN":["2211-5056"],"issn-type":[{"value":"2211-5056","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}